Browse our BRCA2 (BRCA2) ELISA Kits

Full name:
Breast Cancer 2, Early Onset ELISA Kits (BRCA2)
On www.antibodies-online.com are 24 Breast Cancer 2, Early Onset (BRCA2) ELISA Kits from 7 different suppliers available. Additionally we are shipping BRCA2 Antibodies (90) and BRCA2 Proteins (2) and many more products for this protein. A total of 119 BRCA2 products are currently listed.
Synonyms:
AI256696, AW045498, BRCA2, BRCC2, BROVCA2, FACD, FAD, FAD1, FANCB, FANCD, FANCD1, GLM3, PNCA2, RAB163
list all ELISA KIts Gene Name GeneID UniProt
BRCA2 12190 P97929
BRCA2 675 P51587
BRCA2 360254  

Show all species

Show all synonyms

More ELISA Kits for BRCA2 Interaction Partners

Zebrafish Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. Carcinogenesis in zebrafish with combined mutations in tp53 (show TP53 ELISA Kits) and brca2 typically requires biallelic mutation or loss of at least one of these genes.

  2. The novel role of Brca2 in organizing the vertebrate egg nucleus may provide new insights into the origin of ovarian cancer

  3. critical roles for brca2 in ovarian development and tumorigenesis in reproductive tissues

Mouse (Murine) Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. we generated a Brca2 knock-in mouse model lacking exons 4-7 and demonstrated that these exons are dispensable for viability as well as tumor-free survival. This study provides the first in vivo evidence of the functional significance of a minor transcript of BRCA2 that can play a major role in the survival of humans who are homozygous for a clearly pathogenic mutation.

  2. we describe a genetic approach to examine the functional significance of the interaction between BRCA2 and PALB2 (show PALB2 ELISA Kits) by generating a knock-in mouse model of Brca2 carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 (show PALB2 ELISA Kits) and Trp53 (show TP53 ELISA Kits) heterozygosity .

  3. Merit40 (show BABAM1 ELISA Kits) mutation exacerbated ICL-induced chromosome instability in the context of concomitant Brca2 deficiency but not in conjunction with Fancd2 (show FANCD2 ELISA Kits) mutation.

  4. Heterozygous and homozygous Brca2 mutation may lead to dysfunction in T cell populations.

  5. BRCA2 exon 27 domain maintains chromosomal integrity at both stalled and collapsed replication forks consistent with involvement in both replication fork maintenance and double strand break repair.

  6. we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several types of chemotherapy and PARP (show PARP1 ELISA Kits) inhibition.

  7. BRCA2-mediated sequestration of nuclear RAD51 (show RAD51 ELISA Kits) serves to prevent inappropriate DNA interactions.

  8. BRCA2 directly represses the expression of IFN-related genes

  9. the models reveal novel aspects of cancer evolution in carriers of germline BRCA2 mutations, provide new insights into the tumour suppressive role of BRCA2

  10. genetic stability, and hematopoietic differentiation potential of gene-corrected Brca2(Delta) (27/) (Delta) (27) iPSCs, achievements and limitations in the application of current reprogramming approaches in hematopoietic stem cell therapy are also discussed.

Human Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. This study detected monoallelic L1053X mutation causing the same stop codon in BRCA2 protein sequence at the same position in four Sudanese female breast cancer patients out of nine from different families.

  2. Being a male BRCA1 or a BRCA2 mutation carrier or even being clinically defined as having high cancer risk with no known BRCA mutation in men is not associated with any clinically significant risk for developing this rare entity.

  3. A patient with an ampulla of Vater carcinoma was incidentally found to carry the BRCA2 c.156_157insAlu mutation. Further testing of a consecutive series of additional 15 ampullary carcinomas for BRCA1/BRCA2 mutations using a combination of direct founder mutation testing and full gene analysis with next generation sequencing. BRCA2 mutations were observed with a frequency of 14.3% in ampulla of Vater carcinomas.

  4. data from our systematic review and meta-analysis suggests a causal relationship between germline BRCA1/2-pathogenic mutations and the development of Uterine serous carcinoma.

  5. study demonstrates that the individual and combined expression patterns of the DDR (show DDR1 ELISA Kits) molecules PARP1 (show PARP1 ELISA Kits), gammaH2AX (show H2AFX ELISA Kits), BRCA1, and BRCA2 could be predictive of the prognosis of STS (show STS ELISA Kits) patients and suggests that controlling the activity of these DDR (show DDR1 ELISA Kits) molecules could be employed in new therapeutic stratagems for the treatment of STS (show STS ELISA Kits)

  6. radiosensitization was evaluated using the glioblastoma cell line, U87MG-E6, which harbors inactivated p53 (show TP53 ELISA Kits), in comparison with the cell line, HCT116 p53 (show TP53 ELISA Kits) (-/-). We conclude that radiosensitization by arsenite is related to ROS (show ROS1 ELISA Kits) and BRCA2 function.

  7. Data suggest that RAD51 (show RAD51 ELISA Kits), BRCA2, and BRCA1 promote stability of nascent DNA at replication forks; RAD51 (show RAD51 ELISA Kits) prevents MRE11 (show MRE11A ELISA Kits) nuclease (show DCLRE1C ELISA Kits)-mediated degradation of nascent ssDNA; BRCA2 displaces RPA (show RPA1 ELISA Kits) (replication protein A) complex by recruiting RAD51 (show RAD51 ELISA Kits) to protect ssDNA; BRCA1 promotes repair foci following DNA damage and is essential for cell survival. (BRCA = breast cancer recombination protein; RAD51 (show RAD51 ELISA Kits) = Rad51 (show RAD51 ELISA Kits) recombinase (show RAG1 ELISA Kits)) [REVIEW]

  8. we generated a Brca2 knock-in mouse model lacking exons 4-7 and demonstrated that these exons are dispensable for viability as well as tumor-free survival. This study provides the first in vivo evidence of the functional significance of a minor transcript of BRCA2 that can play a major role in the survival of humans who are homozygous for a clearly pathogenic mutation.

  9. Data suggest that modulation of histone deacetylase (show HDAC1 ELISA Kits) (HAT (show MGEA5 ELISA Kits)) activity by an SNP in BRCA2 (breast cancer type 2 susceptibility protein; rs144848, 1342A>C, N372H) is a plausible mechanism of paclitaxel resistance in breast cancer; after HAT (show MGEA5 ELISA Kits) inhibitor treatment, HAT (show MGEA5 ELISA Kits) activity, and paclitaxel sensitivity is restored in heterozygous BRCA2 variant breast cancer cells.

  10. One rare variant in BRCA2 3'UTR (show UTS2R ELISA Kits) was identified in 716 breast cancer cases and 619 controls. Identified variant gives no convincing evidence of potential pathogenicity.

BRCA2 Antigen Profile

Antigen Summary

Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele.

Alternative names and synonyms associated with BRCA2

  • breast cancer 2, early onset (BRCA2) Elisa Kit
  • breast cancer 2, early onset (brca2) Elisa Kit
  • breast cancer 2 (Brca2) Elisa Kit
  • breast cancer 2, early onset (Brca2) Elisa Kit
  • AI256696 Elisa Kit
  • AW045498 Elisa Kit
  • BRCA2 Elisa Kit
  • BRCC2 Elisa Kit
  • BROVCA2 Elisa Kit
  • FACD Elisa Kit
  • FAD Elisa Kit
  • FAD1 Elisa Kit
  • FANCB Elisa Kit
  • FANCD Elisa Kit
  • FANCD1 Elisa Kit
  • GLM3 Elisa Kit
  • PNCA2 Elisa Kit
  • RAB163 Elisa Kit

Protein level used designations for BRCA2

breast and ovarian cancer susceptibility protein 2 , breast cancer 2, early onset , breast cancer type 2 susceptibility protein-like , breast cancer type 2 susceptibility protein homolog , fanconi anemia group D1 protein homolog , BRCA1/BRCA2-containing complex, subunit 2 , breast and ovarian cancer susceptibility gene, early onset , breast cancer 2 tumor suppressor , breast cancer type 2 susceptibility protein , fanconi anemia group D1 protein , truncated breast and ovarian cancer susceptibility protein 2 , breast cancer 2, mutation 1, University of Wisconsin-Madison , breast cancer susceptibility protein 2

GENE ID SPECIES
100064578 Equus caballus
566758 Danio rerio
584780 Strongylocentrotus purpuratus
721981 Macaca mulatta
100397509 Callithrix jacchus
452526 Pan troglodytes
100038818 Xenopus (Silurana) tropicalis
100601625 Nomascus leucogenys
12190 Mus musculus
675 Homo sapiens
360254 Rattus norvegicus
374139 Gallus gallus
474180 Canis lupus familiaris
507069 Bos taurus
493878 Felis catus
Selected quality suppliers for BRCA2 (BRCA2) ELISA Kits
Did you look for something else?